RQS Scoring Log

Retatrutide

Metabolic· Human RCT· Originally scored May 2026 · Updated June 2026· View compound profile →

77 /100

Moderate Evidence

7 dimensions · 100 points total · Methodology by PeptideClear

Previously 59/100 (Moderate) · Updated June 2026 following TRIUMPH-1 Phase 3 readout

Dimension Breakdown

Dimension	Scoring Notes	Score
Study Design Updated	TRIUMPH-1 (Phase 3, n=2,339, 80 weeks, obesity without T2D) announced May 21, 2026. TRIUMPH-4 (Phase 3, obesity + knee OA, 68 weeks) reported December 2025. TRANSCEND-T2D-1 (Phase 3, T2D, 40 weeks) reported March 2026. Multiple completed Phase 3 RCTs now exist across distinct indications — meets the threshold for 25/25. Previously scored 20/25 when only the Phase 2 NEJM paper existed.	25 / 25
Sample Size Updated	TRIUMPH-1 alone enrolled 2,339 participants across four arms (4mg, 9mg, 12mg, placebo). TRIUMPH-4 and TRANSCEND-T2D-1 add further participants. Cumulative enrolled sample is now in the thousands across the Phase 3 program. 16/20 is appropriate — the full TRIUMPH program (TRIUMPH-2, -3, and the cardiovascular outcomes trial enrolling ~10,000) is still reading out, so 20/20 is premature. Previously 8/20 based on the 338-participant Phase 2.	16 / 20
Replication Updated	Multiple Lilly-run Phase 3 trials across different indications and patient populations now constitute the evidence base. This is a meaningful step up from the single Phase 2 study. However, all trials are Lilly-sponsored — no academically independent or third-party replication exists yet. Scored as single group, multiple studies: 10/20. Previously 5/20 (single study). True independent replication remains the gap; this score will move again if post-approval academic work emerges.	10 / 20
Journal Impact Factor	Phase 2 primary results published in NEJM (IF ~96) — the highest-impact journal in medicine. TRIUMPH-1 topline data released as a press announcement; full peer-reviewed publication and ADA 2026 presentation pending. Score reflects existing NEJM publication. Expected to hold or improve once Phase 3 papers are published.	15 / 15
Funding Independence	Eli Lilly funded all trials — Phase 2 and the entire TRIUMPH Phase 3 program. Trials are pre-registered on ClinicalTrials.gov and rigorously conducted, but no independent academic funding source has been identified. Unchanged from original score.	3 / 10
Population Diversity	TRIUMPH-1 enrolled adults with obesity or overweight without T2D; TRIUMPH-4 enrolled obesity + knee OA; TRANSCEND-T2D-1 enrolled T2D patients. Reasonable demographic mix across a predominantly US/global trial design. Moderate score — full diversity data not yet reported in detail from Phase 3. Unchanged from original score.	3 / 5
Researcher h-Index	Lead investigators include Ania Jastreboff (Yale, h-Index 20+) and Juan Frias — both prominent endocrinologists with strong academic profiles. Unchanged from original score.	5 / 5

Sources: Eli Lilly TRIUMPH-1 topline press release, May 21, 2026. Jastreboff et al. 2023, NEJM (Phase 2). TRIUMPH-4 Phase 3 results, December 2025. TRANSCEND-T2D-1, March 2026. ClinicalTrials.gov NCT05394623 and related TRIUMPH identifiers. Primary journal: NEJM (Phase 2). Full Phase 3 peer-reviewed publications pending ADA 2026 and subsequent journal submission.

Note: Retatrutide's TRIUMPH-1 result (28.3% mean body weight reduction at 80 weeks on 12mg; 30.3% at 104 weeks in the BMI ≥35 extension subgroup) is the largest weight loss reported in a Phase 3 obesity trial to date, exceeding tirzepatide's SURMOUNT-1 result. The evidence grade and RQS band are Moderate rather than Strong because the full peer-reviewed Phase 3 publication is pending, independent replication does not yet exist, and the broader TRIUMPH program is still reading out. Funding Independence remains the structural ceiling on this score — all evidence is Lilly-sponsored.

Scored by the PeptideClear editorial team using publicly available literature. Sources: PubMed and ClinicalTrials.gov (study design, sample size, replication) · ScimagoJR (journal impact factor) · Google Scholar (researcher h-Index) · Primary papers and press releases (funding disclosure). Scores are reviewed as new research is published.